-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9

Benzinga·06/25/2026 14:54:37
Listen to the news
JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and lowers the price target from $12 to $9.